Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Progressive supranuclear palsy].

C G Goetz1

  • 1Rush University, Presbyterian--St Luke's Medical Center, 1725, West Harrison street, Suite 755, Chicago, IL 60612, USA. cgoetz@rush.edu

Revue Neurologique
|May 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same author

Revue neurologique·2017
Same author

Charcot, hysteria, and simulated disorders.

Handbook of clinical neurology·2016
Same author

Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.

European journal of neurology·2014
Same author

Continuous in-home monitoring of essential tremor.

Parkinsonism & related disorders·2013
Same author

Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale.

European journal of neurology·2013
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Progressive supranuclear palsy (PSP) is a rare parkinsonian syndrome. Understanding its clinical progression, particularly the onset of key incapacities, is crucial for developing effective neuroprotective treatments.

Area of Science:

  • Neurology
  • Neurodegenerative Diseases

Context:

  • Progressive supranuclear palsy (PSP) is a rare parkinsonian syndrome, significantly less common than Parkinson's disease.
  • While sharing some symptoms with Parkinson's disease, PSP presents distinct clinical and histopathological features.
  • Accurate diagnosis relies on clinical signs due to the absence of a biological marker.

Purpose:

  • To establish the probability of histopathological diagnosis through recognized clinical signs.
  • To categorize PSP into probable and possible types based on NINDS criteria.
  • To inform research on new treatments by understanding the natural course of clinical incapacity.

Summary:

  • A longitudinal study tracked 50 patients with probable PSP, analyzing symptom onset and the development of key incapacities (mobility, speech, feeding).

Related Experiment Videos

  • The Unified Parkinson's Disease Rating Scale was used to detect these critical signs.
  • Kaplan-Meier analysis indicated a mean disease duration of 50 months before the onset of one of these major incapacities.

    • Impact:

    • Identifies a critical 50-month window for potential therapeutic intervention in PSP.
    • Highlights the need for neuroprotection research focused on slowing disease progression.
    • Provides essential data for future clinical trials targeting PSP treatment and management.